Related Experiment Video

Updated: Oct 11, 2026

Laminectomy and Spinal Cord Window Implantation in the Mouse
06:59

Laminectomy and Spinal Cord Window Implantation in the Mouse

Published on: October 23, 2019

COX-2 in brain and spinal cord implications for therapeutic use

C Hoffmann1

  • 1Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen-Nuremberg, Germany.

Current Medicinal Chemistry
|October 18, 2000
PubMed

Insights

Cyclooxygenase-2 (COX-2) plays a crucial role in pain mediation and fever development in the central nervous system. Selective COX-2 inhibitors show promise for treating pain and neurodegenerative diseases with improved safety.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Inflammation Research

Background:

  • Initial expectations of anti-inflammatory treatment focused on inducible COX-2, but constitutive COX-2 presence in the kidney, stomach, and CNS challenged this hypothesis.
  • Constitutive COX-2 is the predominant cyclooxygenase isoform in the brain and spinal cord, regulated by various mediators.

Purpose of the Study:

  • To elucidate the physiological and pathophysiological roles of constitutive COX-2 in animal models.
  • To investigate the involvement of COX-2 in pain processing, fever development, and brain maturation.

Main Methods:

  • Animal models were used to study COX-2 expression and function.
  • Experimental induction of peripheral inflammation was employed to assess spinal cord responses.
  • Analysis of COX-2 gene and protein expression, prostaglandin synthesis, and its role in brain endothelial cells.

Main Results:

  • Peripheral inflammation significantly induced COX-2 expression and prostaglandin synthesis in the spinal cord, indicating its role in pain mediation.
  • COX-2 in brain endothelial cells was linked to fever development, suggesting selective COX-2 inhibitors may be more effective antipyretics.
  • New findings highlight COX-2's role in brain differentiation and maturation, suggesting potential therapeutic applications for neurodegenerative diseases like Alzheimer's.

Conclusions:

  • Constitutive COX-2 is significantly involved in pain processing within the spinal cord and fever regulation.
  • Selective COX-2 inhibitors demonstrate a favorable safety profile compared to non-selective inhibitors, offering potential for treating pain and neurodegenerative conditions.
  • Further clinical evaluation will determine the broader therapeutic applications of selective COX-2 inhibitors in pain management and neurological disorders.

More Related Videos

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Related Concept Videos

Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Local Anesthetics: Clinical Application as Spinal Anesthesia01:11

Local Anesthetics: Clinical Application as Spinal Anesthesia

Spinal anesthetics are given during lower abdomen and limb surgeries to block sensory and motor neurons. They are administered in the mid to low lumbar regions, primarily acting on the cauda equina's nerve roots. The blockade level depends on the local anesthetic (LA) concentration. Usually, low LA concentrations are sufficient to block sensory fibers, while only high LA concentrations block motor fibers. Other factors like injection volume and speed, the patient's posture, and the drug...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...